Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
0
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
0
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198897
Dec 15, 2023 - Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
0
Best Momentum Stocks to Buy for December 13th
https://www.zacks.com/commentary/2197102/best-momentum-stocks-to-buy-for-december-13th?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2197102
Dec 13, 2023 - GLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023.
0
New Strong Buy Stocks for December 13th
https://www.zacks.com/commentary/2195934/new-strong-buy-stocks-for-december-13th?cid=CS-ZC-FT-zacks_1_rank_additions-2195934
Dec 13, 2023 - TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
0
Pages: 12
<Page 2